9 Amendments of Catherine BEARDER related to 2018/2775(RSP)
Amendment 6 #
Recital C
C. whereas Cannabis products that are usthe term “medical cannabis” should be distinguished forom medicinal purposes are broadly referred to as “medical cannabis”;es derived from Cannabis which have undergone clinical trials and are regulatory approved,
Amendment 20 #
Recital J
J. whereas a review of existing scientific literature on the subject of medical cannabis used in a medical setting provides conclusive or substantial evidence that cannabis and cannabinoids have therapeutic effects such as in the treatment of chronic pain in adults (e.g. in cancer diseases), as antiemetics in the treatment of chemotherapy-induced nausea and vomiting or for improving patient-reported multiple sclerosis spasticity symptoms;
Amendment 23 #
Recital K
K. whereas there is limited evidence that cannabis or cannabinoids are effective for increasing appetite and decreasing weight loss associated with HIV/AIDS, improving clinician-measured multiple sclerosis spasticity symptoms, improving symptoms of Tourette syndrome, improving symptoms of posttraumatic stress disorder;
Amendment 38 #
Paragraph 1
1. Stresses the need for the Commission and national authorities to draw a clear distinction between medical cannabis based medicines approved by the EMA (or other national regulatory agencies), medical cannabis (not supported by clinical trials) and other applications of cannabis;
Amendment 45 #
Paragraph 2
2. Considers that research on medicalthe potential benefits of medicines derived from cannabis has been underfunded and should be properly addressed under the next Framework Programme 9;
Amendment 65 #
Paragraph 7
7. Calls on Member States to encourage increased knowledge among medical professionals regarding the use of such cannabis-based medicine and consider allowing doctors to freely use their professional judgement to prescribe cannabis anregulatory approved cannabis-based medicines to patients with relevant conditions, and allow pharmacists to lawfully honour those prescriptions; highlights the need for training and access to literature for medical staff - medical students, medical doctors and pharmacists;
Amendment 70 #
Paragraph 9
Amendment 74 #
Paragraph 9 a (new)
9a. Calls on the Commission to work with Member States to ensure safe and controlled cannabis used for medicinal purposes can only be from cannabis derived products that have been through clinical trials, regulatory assessment and approval,
Amendment 79 #
Paragraph 10
10. Underlines how a comprehensive regulation of medical cines deriving from Cannabis would translate into additional resources for public authorities, would limit the black market for medical cannabis consumption, would help control points of sale, would limit the access of this substance to minors and would give a legal and safe access to patients for its medicinal use - with particular precautions for young people and pregnant women;, ensure quality and accurate labelling of medicines and ensure legal and safe patient access to regulatory approved medicines,